Zambruno, Giovanna; Borradori, Luca (2008). Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. Journal of Investigative Dermatology, 128(12), pp. 2745-7. New York, N.Y.: Nature Publishing 10.1038/jid.2008.330
Full text not available from this repository. (Request a copy)The anti-CD20 mAb rituximab, first approved for use in B-cell malignancies, is increasingly used to treat a variety of autoimmune diseases. Two studies in this issue investigate the effects of rituximab in pemphigus. Rituximab induces not only a depletion of all B cells and a decline of antidesmoglein autoantibodies but also a decrease in desmoglein-specific T cells. Furthermore, B-cell populations recovered after treatment were modified. These novel aspects may contribute to the clinical responses observed in patients.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Borradori, Luca |
ISSN: |
0022-202X |
ISBN: |
18997839 |
Publisher: |
Nature Publishing |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 15:04 |
Last Modified: |
05 Dec 2022 14:19 |
Publisher DOI: |
10.1038/jid.2008.330 |
PubMed ID: |
18997839 |
Web of Science ID: |
000261062500001 |
URI: |
https://boris.unibe.ch/id/eprint/27642 (FactScience: 109768) |
Actions (login required)
 |
Edit item |